Olaris, Inc

Directions Website Contact the business

Olaris, Inc Combining metabolomics and machine learning into precision diagnostics for the entire patient journey

Friday Fun Fact: A transplanted kidney can start making urine while the patient is still on the operating table! 🩺Once t...
10/16/2026

Friday Fun Fact: A transplanted kidney can start making urine while the patient is still on the operating table! 🩺

Once the new kidney is connected to the recipient's blood supply, it can get to work right away.

🎥 Want to see it happen? Watch Northwestern Medicine transplant surgeon Dr. Dinee Simpson perform a kidney transplant and show the new kidney making urine.
⚠️ Warning: This video shows real human tissue, organs and surgical tools. youtu.be/zPXphpl7gco

But a transplant isn't the end of the story. Keeping the new kidney healthy for as long as possible is the next challenge. That's why Olaris developed myOLARIS® -KTdx, a non-invasive assay that profiles metabolites in urine to support surveillance of kidney graft injury in kidney transplant recipients. https://www.myolaris.com/myolaris-ktdx

Olaris builds precision diagnostics with one integrated process, metabolomics, machine learning, and biology, woven toge...
10/15/2026

Olaris builds precision diagnostics with one integrated process, metabolomics, machine learning, and biology, woven together to reveal what's happening in disease.

myOLARIS® -KTdx supports surveillance of kidney graft injury in transplant recipients. It's our first commercial product — the first clinical proof of what this platform can do.

Olaris is now developing a new, non-invasive tool that could give early indications of graft injury in children. myOLARIS® -pKTdx starts with a different data set and different clinical questions than myOLARIS® -KTdx, which was built for adults. As Dr. Elizabeth O'Day puts it, "kids are not just little adults, and they need products developed specifically for them."

Same process. Different diagnostic. As the myOLARIS® pipeline grows, the populations we serve and the questions we're answering change — the process behind it doesn't.

Find out more: myolaris.com/diagnostics-pipeline

Our is 6-sulfatoxymelatonin (aMT6s) — the metabolite of melatonin, the hormone that tells your body it's time for slee...
10/13/2026

Our is 6-sulfatoxymelatonin (aMT6s) — the metabolite of melatonin, the hormone that tells your body it's time for sleep.

Melatonin is released in the dark. It travels through the bloodstream, gets converted in the liver, and shows up in urine as aMT6s — no blood draw required, just a urine sample and a clear signal.

Melatonin levels aren't fixed. They decline with age. Shift work and light exposure at night disrupt them too, and both are tied to poorer sleep.

Diet plays a role. Nuts contain tryptophan, a melatonin building block, along with some melatonin of their own. In one study, adults who ate 40 grams of walnuts a day for eight weeks saw their evening aMT6s levels rise — along with better sleep quality and less daytime sleepiness, highlighting the crosstalk between diet and body function.

At Olaris, we read metabolite patterns like this one to reveal what's happening in the body.

Find out more: myOlaris.com

Sources: Wei T, Li C, Heng Y, Gao X, Zhang G, Wang H, Zhao X, Meng Z, Zhang Y, Hou H. Sleep Med. 2020;75:502-509. doi: 10.1016/j.sleep.2020.09.018; Zerón-Rugerio MF, Ibarra-Picón A, Diez-Hernández M, et al. Food Funct. 2025;16(18):7023-7035. doi: 10.1039/d5fo00971e.

Meet Dr. Meredith Hanel, our Q3 Star of the Quarter.Meredith is part of the Olaris communications team. She writes the p...
10/09/2026

Meet Dr. Meredith Hanel, our Q3 Star of the Quarter.

Meredith is part of the Olaris communications team. She writes the posts you read here, and she checks and triple checks each one before it reaches you.

"On our communications team, Meredith is truly a rock star. She writes all of our copy across our social channels, checks and triple checks everything, and is someone I can utterly trust. We all see the fruit of her hard work and are grateful to have her on the team," said Dr. Elizabeth O'Day, founder, CEO and CSO.

Please join us in congratulating Meredith!

Glycolysis is found in some form in every domain of life — Eukarya, Bacteria, and Archaea. It's one of the oldest proces...
10/09/2026

Glycolysis is found in some form in every domain of life — Eukarya, Bacteria, and Archaea. It's one of the oldest processes in biology, older than oxygen itself on Earth. No oxygen needed. Glycolysis breaks down glucose, a six-carbon sugar, into two three-carbon molecules called pyruvate. Those pyruvate molecules become building blocks for other molecules in the cell. The pathway also makes ATP for energy and NADH, a molecule that helps generate even more energy down the line.

Same steps. Every cell. Every tissue. That consistency in glycolysis and other metabolic pathways mean they produce patterns that are predictable, so a shift in those patterns can point to something worth a closer look.

At Olaris, we read metabolite patterns like these to build and power diagnostics.
Find out more: myOlaris.com

Our , 6-sulfatoxymelatonin, is the metabolic breakdown product of melatonin, a hormone we produce more of in autumn as ...
10/08/2026

Our , 6-sulfatoxymelatonin, is the metabolic breakdown product of melatonin, a hormone we produce more of in autumn as the hours of sunlight decrease and can make us feel a little more sluggish.

6-sulfatoxymelatonin is an example of a metabolite present in urine that is a readout of our body responding to our environment. Melatonin is released from the pineal gland under the control of the internal circadian pacemaker in the suprachiasmatic nucleus (SCN) of the brain, produced during the dark and suppressed during the day. Melatonin follows a strong circadian rhythm in people exposed to a normal light-dark cycle.

Melatonin released by the pineal gland in the brain enters circulation and is metabolized in the liver, where 90% is excreted in urine as 6-sulfatoxymelatonin. That makes 6-sulfatoxymelatonin a useful, noninvasive way to track melatonin in circadian rhythm research.

Metabolites are a biochemical record of everything shaping the body, like cellular activity, environmental inputs, medication, and disease processes. At Olaris, we read metabolite patterns to build and power diagnostics that reveal what is happening in disease.

Find out more: myOlaris.com

Sources: Arendt J, Aulinas A. In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. https://www.ncbi.nlm.nih.gov/books/NBK550972/; St Hilaire MA, Lockley SW. Methods Mol Biol. 2022;2550:21-28. doi: 10.1007/978-1-0716-2593-4_4. https://link.springer.com/protocol/10.1007/978-1-0716-2593-4_4

Olaris built a precision diagnostics platform that reads metabolites, the small molecules the body produces as it functi...
10/06/2026

Olaris built a precision diagnostics platform that reads metabolites, the small molecules the body produces as it functions, to reveal what's happening in disease. The myOLARIS® platform runs on one integrated, reproducible process, from data acquisition through machine learning to biological interpretation.

myOLARIS® -KTdx is the first diagnostic built on that process. It's a urine-based laboratory-developed test designed to support surveillance of kidney graft injury in transplant recipients, including borderline rejection, subclinical and clinical rejection, and polyomavirus-associated nephropathy (PVAN). The test is processed through our CLIA-certified laboratory and holds its own PLA code (0542U).

myOLARIS® -KTdx is the first clinical proof of what the platform can do. myOLARIS® is built to read metabolite changes that come from any disease, anywhere in the body, and that same integrated process applies to every diagnostic that comes next.

Find out more: myOlaris.com/diagnostics-pipeline

Metabolomics is the study of small molecules — metabolites — that the body produces as it functions. Metabolites are a r...
10/02/2026

Metabolomics is the study of small molecules — metabolites — that the body produces as it functions. Metabolites are a running record of the chemical reactions happening throughout the body, and they show up in fluids like urine and blood. By looking at how metabolite types and levels change, metabolomics can reveal what's happening in the body right now, not just what might happen later, including in disease.

Here's the challenge: most groups in this field split the process into pieces — one team acquires the data, another runs the statistics, a third interprets the biology. Different methods, different teams, and if everyone is not aligned, reproducibility suffers.

Olaris takes a different approach. One team runs the full process — acquiring data through NMR and mass spectrometry, then integrating it with machine learning and biological interpretation — to extract meaningful metabolite patterns as potential disease biomarkers, in ways the field hasn't seen before.

Find out more: myOlaris.com

Today, Olaris Founder, CEO, and CSO Dr. Elizabeth O'Day is at Washington University in St. Louis with the kidney transpl...
10/01/2026

Today, Olaris Founder, CEO, and CSO Dr. Elizabeth O'Day is at Washington University in St. Louis with the kidney transplant team, discussing myOLARIS® -KTdx, a urine-based test designed to support surveillance of kidney graft injury — including borderline rejection, subclinical and clinical rejection, and polyomavirus-associated nephropathy (PVAN).

She'll also meet with WUSTL's pediatric kidney transplant team about myOLARIS® -pKTdx, a non-invasive urine assay in development for monitoring kidney graft injury in pediatric transplant recipients.

Our platform integrates metabolomics, machine learning, and biology to build and power diagnostics that reach beyond transplant. That's why Dr. O'Day is also meeting separately with WUSTL's oncology team today.

Our platform follows the clinical need.

Find out more: myOlaris.com

Olaris is pleased to have received a tax incentive award from the Massachusetts Life Sciences Center (MLSC), a quasi-pub...
09/30/2026

Olaris is pleased to have received a tax incentive award from the Massachusetts Life Sciences Center (MLSC), a quasi-public economic development investment agency that supports the growth of the life sciences in Massachusetts. Olaris is among 38 companies receiving MLSC tax incentives announced this week by the Healey-Driscoll Administration to support research, development and manufacturing operations in the state.

"We're grateful for this support from the Massachusetts Life Sciences Center and Healey-Driscoll Administration. Massachusetts is where Olaris was built, and this award helps us add the scientific talent we need to bring our metabolomic diagnostics to those that need it," said Dr. Elizabeth O'Day, CEO, CSO and founder of Olaris. "Expanding in Massachusetts matters to us."

Read the full MLSC Tax Incentive Program announcement: https://www.masslifesciences.com/governor-healey-announces-40-million-to-grow-massachusetts-life-sciences-industry-create-more-than-1600-jobs/

Address

175 Crossing Boulevard, Suite 410
Framingham, MA
01702

Opening Hours

Monday 8:30am - 6pm
Wednesday 8:30am - 6pm

Website

Alerts

Be the first to know and let us send you an email when Olaris, Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Olaris, Inc:

Shortcuts

Share

Category